William Jordan is co-chair of the Litigation & Trial Practice Group. He concentrates his practice on business litigation, government and internal corporate investigations, corporate ethics and compliance matters, and antitrust law. Bill is a member of the firm's Government Investigations & Special Matters Team and leads its Health Care Litigation Team. He frequently represents hospitals, pharmaceutical companies, insurers, health care providers, chemical manufacturers, telecommunications and technology providers, and financial services companies in offensive and defensive litigation, corporate compliance matters and government investigations. He also serves as outside ethics and compliance counsel to a number of companies, including multinational chemical and manufacturing companies and health care providers. Bill has represented companies in civil litigation throughout the country in complex matters involving unfair trade practices, antitrust law, health care regulation, civil RICO and the False Claims Act. He also has represented clients in government and congressional investigations involving health care fraud, the NSA’s terrorist surveillance program, computer crime and the Foreign Corrupt Practices Act.
From 2001-2003, Bill served as a senior official in the Department of Justice—from 2001-2003, as Senior Counsel to the Assistant Attorney General for the Civil Division; and in 2003, as Senior Counsel to the Associate Attorney General of the United States.
- Represented nation’s largest publicly-traded hospital chain in civil and criminal investigations throughout the country involving health care fraud matters. Negotiated favorable settlement of many investigations and obtained judicial dismissal of one matter involving allegedly unauthorized medical procedures.
- Represented New Orleans hospitals in criminal investigations and congressional hearings related to their response to Hurricane Katrina, including allegations that patients were euthanized in the immediate aftermath of the storm.
- Represented clients in state Attorneys General, Medicaid Fraud Control Unit, and federal investigations in over 20 states and in every federal circuit.
- Obtained $10.3MM judgment for a private college in civil RICO claim alleging fraud in theft of assets involving timber and real estate interests.
- Defended major telecommunications company in multiple class actions alleging that it had impermissibly revealed confidential customer information to government through the National Security Agency’s Terrorist Surveillance Program.
- Represented individual in Senate Judiciary Committee hearing related to alleged firing of U.S. Attorneys and political hiring at Department of Justice.
- Conducted numerous internal investigations related to alleged government fraud, FCPA issues and antitrust matters.
- Serve as outside global ethics and compliance counsel to world’s second largest chemical company.
-
Bill Jordan was quoted in a Global Trade magazine article discussing how giving business gifts to a foreign partner could possibly be viewed as a violation under the strict Foreign Corrupt Practices Act (FCPA) rules.
October 4, 2012
In the Press
-
One hundred and forty-seven Alston & Bird attorneys have been selected for inclusion in the 2013 edition of The Best Lawyers in America. The publication is universally regarded as among the few definitive guides to legal excellence, and its rankings are based on an exhaustive peer-review survey in which more than 36,000 leading attorneys cast almost 4.4 million votes on the legal abilities of other lawyers in their practice areas.
September 18, 2012
In the Press
-
Bill Jordan was quoted in an article for the FCPA Report’s two-part series titled “Designing a Facilitation Payments Policy to Minimize Liability and Retain Flexibility,” which discusses how most other jurisdictions prohibit facilitation payments to foreign officials and how some facilitation payments may violate local laws of foreign countries.
August 10, 2012
In the Press
-
September 7, 2010
In the Press
-
In recent years, the pharmaceutical industry has been a frequent target of Foreign Corrupt Practices Act (FCPA) investigations. Since 2009, when Assistant Attorney General Lanny Breuer warned that the Department of Justice (DOJ) would be “intensely focused on rooting out foreign bribery in [the pharmaceutical] industry,” eight of the world’s 10-largest drugmakers have indicated that they may be facing FCPA liability, and many more have received letters of inquiry from DOJ. The government has paid particular attention to potentially improper payments associated with clinical trials conducted abroad. This article discusses recent developments in this arena and how pharmaceutical companies and medical device makers can best protect themselves from FCPA liability.
November 26, 2012
Publications
-
16 January 2012
Publications
-
"Congress Broadens Scope of FCA; President Creates Health Care Fraud Prevention Team," Compliance Perspectives, July-August 2009.
July-August 2009
-
September 2008
-
Summer 2007
Publications
-
"A Culture of Waiver: Compelled 'Voluntary' Waiver of the Attorney-Client and Work-Product Privileges," BNA's Corporate Counsel Weekly, April 4, 2007.
April 2007
-
Fall 2004
-
1 August 2004
Publications
-
Fall/Winter 2001
Past Events
-
January 24-25, 2013
Seminar
-
June 28, 2012
Seminar
-
May 22-23, 2012
Seminar
-
May 2, 2012
Seminar
-
March 20, 2012
Seminar
-
February 10-11, 2011
Seminar
-
January 27, 2011
Seminar
-
October 8, 2010
Seminar
-
September 2, 2010
Seminar
-
October 23, 2009
Seminar